Vaerloese, Denmark

Mette Dahl Andersen

USPTO Granted Patents = 6 

 

Average Co-Inventor Count = 8.0

ph-index = 2

Forward Citations = 41(Granted Patents)


Company Filing History:


Years Active: 2014-2018

Loading Chart...
Loading Chart...
6 patents (USPTO):

Title: Mette Dahl Andersen: Innovator in Medical Biotechnology

Introduction

Mette Dahl Andersen is a prominent inventor based in Vaerloese, Denmark. She has made significant contributions to the field of medical biotechnology, holding a total of six patents. Her work focuses on innovative solutions for treating coagulopathies and developing binding proteins for therapeutic applications.

Latest Patents

One of her latest patents is titled "Targeting tissue factor to activated platelets." This invention relates to procoagulant fusion proteins, polynucleotides that encode these fusion proteins, and cells that express them. The invention aims to provide treatment options for individuals suffering from coagulopathies, such as hemophilia A and B, with or without inhibitors. Another notable patent is "Human CD30 ligand antigen binding proteins," which includes compositions and methods related to human CD30L antigen binding proteins. This patent encompasses polynucleotides encoding these proteins, vectors, host cells, and pharmaceutical compositions, along with methods for their production and use.

Career Highlights

Mette has worked with leading companies in the biotechnology sector, including Novo Nordisk A/S and Amgen Inc. Her experience in these organizations has allowed her to develop and refine her innovative ideas, contributing to advancements in medical treatments.

Collaborations

Throughout her career, Mette has collaborated with notable colleagues, including Susanne Nedergaard Grell and Peder Lisby Noerby. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking medical solutions.

Conclusion

Mette Dahl Andersen is a distinguished inventor whose work in medical biotechnology has the potential to transform treatment options for patients with coagulopathies. Her innovative patents and collaborations highlight her commitment to advancing healthcare through scientific research and development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…